TerminatedPhase 2

TDCS and Aphasia Therapy in the Chronic Phase After Stroke

Stopped: Reason unknown

Belgium25 participantsStarted 2017-11-24

Plain-language summary

This study evaluates the neuromodulatory effect of combined tDCS and aphasia therapy in patients in the chronic phase after stroke. Half of the participants will receive aphasia therapy and tDCS, the other half will receive aphasia therapy and sham-tDCS.

Who can participate

Age range18 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosed with mild to moderate aphasia (Token Test Score between 7 and 40) after a first left hemispheric ischemic or hemorrhagic stroke * Inclusion \> 6 months post-stroke * Age 18 - 85 years * Being right-handed (\> +8 on the questionnaire for handedness, Van Strien) * Mothertongue: Dutch * Imaging (CT or MRI) prior to inclusion (in patient file), standard of care in the acute phase * Signed Informed Consent (attachment 1) Exclusion Criteria: * History of other diseases of the central nervous system, psychological disorders and (developmental) speech and or language disorders * Serious non-linguistic, cognitive disorders (as documented in the patients' medical history and inquired in the anamneses) * Prior brain surgery * Excessive use of alcohol or drugs * New neurological symptoms between the acute stage and inclusion

What they're measuring

Change in naming performance assessed with the Boston Naming Test

Timeframe: baseline, 3 weeks, 3 +/-1 month

Trial details

NCT IDNCT03305614

SponsorUniversity Hospital, Ghent

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-04-18

View on ClinicalTrials.gov More Aphasia Following Cerebral Infarction trials